<DOC>
	<DOCNO>NCT00767299</DOCNO>
	<brief_summary>The study Korean woman postmenopausal also suffer osteoporosis . The study test woman give 20 mg arzoxifene day six month less severe level osteoporosis woman take arzoxifene . All patient receive 500 mg elemental calcium 400 600 IU Vitamin D daily start 4 week prior study drug administration continue 6 month therapy .</brief_summary>
	<brief_title>A Study Arzoxifene Treat Korean Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Present osteoporosis base total hip , femoral neck lumbar spine BMD Tscore less equal 2.5 must never osteoporotic fragility fracture . Are ambulatory 60 85 year age , inclusive . Aside diagnose osteoporosis ( Inclusion Criterion [ 1 ] ) , woman must free severe chronically disable condition , life expectancy least 5 year opinion investigator , expect remain ambulatory throughout entire study , expect return followup visit . Had last natural menstrual period least 2 year begin study . Are able comprehend requirement procedure study provide inform consent enter study . Have least two lumbar vertebra ( L1 L4 ) evaluable via dual energy Xray absorptiometry ( DXA ) lateral thoracic lumbar spine xray film adequately evaluate exist vertebral fracture screen . Have centrally read total hip , femoral neck lumbar spine Tscore le equal 2.5 Have know current metabolic bone disorder low bone mass , hyperparathyroidism , renal osteodystrophy , osteomalacia . Have know , suspect , history carcinoma breast estrogendependent neoplasia ( e.g. , endometrial uterine carcinoma ) , except hysterectomized patient history carcinoma situ uterus . For cancer , disease free remission cancer 5 year , except excise superficial lesion , basal cell carcinoma squamous cell carcinoma skin . Have demonstrate suspect allergy raloxifene arzoxifene Have unexplained abnormal vaginal bleeding within 6 month prior Visit 1 Visit 1 Visit 2 . Are experience clinically severe postmenopausal symptom may require estrogenreplacement therapy . Have history suggestion ultrasound pelvic examination preexist gynecologic abnormality would require gynecologic treatment ( e.g. , ovarian cyst , large fibroid , undiagnosed adnexal mass ) baseline endometrial thickness &gt; 5 mm . Have Papanicolaou 's test show malignant premalignant finding . Have active past history thromboembolic event Have active past history atrial fibrillation . Have history cerebrovascular accident document transient ischemic attack time past . Have acute chronic liver disease define alanine aminotransaminase ( ALT ) &gt; 100 U/L , gammaglutamyl transferase ( GGT ) &gt; 400 U/L , late stage cirrhosis without transaminase elevation . Have impair kidney function ( serum creatinine &gt; 177 micromol/L &gt; 2.0 mg/dL ) . Have vitamin D deficiency prior enrollment ( Visit 2 ; 25hydroxyvitamin D less than10 ng/mL le 24.9 nmol/L ) . Have know , severe , untreated malabsorption syndrome . Have endocrine disorder require pharmacologic therapy except type II diabetes hypothyroidism . Patients stable dose thyroid replacement therapy 6 month precede randomization ( Visit 2 ) clinically euthyroid opinion investigator may enroll trial . Consume excess alcohol abuse drug Represent unacceptable medical psychiatric risk treatment investigational drug Have active history seizure disorder .</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>